MIS-C

MIS - C
  • 文章类型: Journal Article
    儿童多系统炎症综合征(MIS-C)是一种在COVID-19大流行的早期留下印记的疾病,由于影响多个身体系统的不同病程和症状。这是一种在与感染SARS-CoV-2病毒的人接触约2-6周后在儿科患者中发展的病症。在许多情况下,MIS-C导致多器官衰竭,特别严重的并发症涉及心血管系统,表现为低血压,各种心律失常,心肌炎或冠状动脉病变类似于川崎病。目前,MIS-C的发病率约为每1000名儿童1-3名,由于对6个月以下的儿童引入了针对SARS-CoV-2病毒的免疫接种,近年来呈下降趋势。在我们的论文中,我们介绍了一个患有严重MIS-C病程并伴有许多心血管和神经系统并发症的患者的病例,通过给予生物治疗来控制疾病的症状。我们还对有关该主题的文献进行了回顾,这表明这种疾病可以有多少不同的方面,医生仍然需要保持警惕,因为有严重的MIS-C病例,尤其是未接种疫苗的患者。
    Multisystem inflammatory syndrome in children (MIS-C) is a disease that made its mark in the early days of the COVID-19 pandemic due to the diverse course and symptoms affecting multiple body systems. It is a condition that develops in pediatric patients about 2-6 weeks after contact with a person infected with the SARS-CoV-2 virus. In many instances, MIS-C has caused multiple organ failure, with particularly severe complications involving the cardiovascular system and manifesting as hypotension, various cardiac arrhythmias, myocarditis or coronary artery lesions resembling those seen in Kawasaki disease. Currently, the incidence of MIS-C is about 1-3 per 1000 children, with a decreasing trend in recent years due to the introduction of immunization against the SARS-CoV-2 virus for children as young as 6 months. In our paper, we present the case of a patient with a severe course of MIS-C with numerous cardiovascular and neurological complications, in whom the symptoms of the disease were managed by administering biological treatment. We also present a review of the literature on the subject, which shows how many different facets this disease can have and that physicians still need to remain alert, as there are cases of severe MIS-C, especially in unvaccinated patients.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    评估阿拉伯国家的巨大动脉瘤(GiAn)患病率并检查其影响因素;并回顾川崎病(KD)的出版趋势和阿拉伯国家之间的合作。进行了范围界定的文献综述,以分析整个阿拉伯世界的出版物,从1978年到2023年,横跨16个国家。收集的文章是数据库搜索与呼吁阿拉伯川崎病倡议(Kawarabi)成员共享非PubMed出版物的结合。超过45年,50篇文章来自阿拉伯国家,KD研究产出年均增长率为30%。出版物在病例报告(42%)和机构系列(52%)之间平均分配。阿联酋的发展中国家的研究生产率落后,KSA和埃及,占总出版物的64%。在26个机构系列中,报告了1264例KD患者中的256例冠状动脉瘤(CAA)。其中,25例CAA为GiAn(患病率1.43%[范围0-12.5%])。初始KD误诊率为4%,不完全KD(iKD)平均为10.6%。未报告iKD的系列(38.5%)与较高的CAA患病率相关,但不是Gian的.较长的发烧持续时间是GiAn的关键因素(OR5.06,95CI1.51-17)。这篇评论揭示了45年来阿拉伯世界KD的研究前景。初步误诊,未经治疗的病例,iKD的延迟诊断和漏报是导致流行病学低估的因素,解释了更高的GiAn患病率。这就要求采取战略干预措施,加强这些国家的KD研究,与Kawarabi的任务保持一致。
    To evaluate giant aneurysms (GiAn) prevalence in Arab countries and examine contributing factors; and to review Kawasaki disease (KD) publication trends and collaborations among Arab nations. A scoping literature review was conducted to analyze the publications across the Arab world, spanning 16 countries from 1978 to 2023. The collected articles were a combination of database search with a call on Kawasaki Disease Arab Initiative (Kawarabi) members to share non-PubMed publications. Over 45 years, 50 articles originated from the Arab Countries with a 30% average annual growth rate in KD research output. Publications were evenly split between case reports (42%) and institutional series (52%). Research productivity lagged in developing nations with UAE, KSA and Egypt, contributed to 64% of total publications. Among 26 institutional series, 256 coronary artery aneurysms (CAA) from a total of 1264 KD cases were reported. Of those, 25 CAA were GiAn (prevalence 1.43% [range 0-12.5%]). The initial KD misdiagnosis rate was 4%, and incomplete KD (iKD) averaged 10.6%. Series (38.5%) that did not report iKD correlated with a higher prevalence of CAA, but not of GiAn. Longer fever duration emerged as a pivotal factor for GiAn (OR 5.06, 95%CI 1.51-17). This review unveils the research landscape of KD in the Arab world over 45 years. Initial misdiagnosis, untreated cases, delayed diagnosis and underreporting of iKD are contributing factors for an underestimated epidemiology, explaining the higher GiAn prevalence. This calls for strategic interventions to enhance KD research in these countries, aligning with Kawarabi\'s mission.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Case Reports
    回盲肠肠套叠(ICI)是最常见的腹部急症,也是幼儿肠梗阻的原因,携带高死亡率和发病率的风险。肠道病毒感染性和炎性综合征是肠套叠(回肠和回肠)的已知诱因,可引起肠系膜淋巴增生,这可能是肠系膜淋巴增生的主要原因。胃肠道(GI)症状在2019年冠状病毒病(COVID-19)感染儿童中很常见,一部分患者在就诊时仅有胃肠道主诉。迄今为止,在多例报道的病例中,已经假设并建议将COVID-19作为儿童肠套叠的触发因素,在疾病的急性期和作为儿童多系统炎症综合征(MIS-C)的一部分。我们介绍了一名7个月大的男性,由于病毒共同感染和住院期间MIS-C的逐渐出现,他患上了ICI并成为诊断困境。我们正在描述这个演讲,试图扩大对COVID-19和MIS-C在这个年轻而独特的年龄组的影响的理解。
    Ileocecal intussusception (ICI) is the most common abdominal emergency and cause of intestinal obstruction in young children, carrying a high risk of mortality and morbidity. Enteric viral infectious and inflammatory syndromes are known triggers for intussusception (ileoileal and ileocolic) by causing mesenteric lymphoid hyperplasia that may act as a leading point allowing the bowel to invaginate into itself. Gastrointestinal (GI) symptoms are common in children with coronavirus disease 2019 (COVID-19) infection, with a subset of patients solely having GI complaints at the time of presentation.  COVID-19 as a trigger for intussusception in children has been hypothesized and suggested in multiple cases reported to date, both during the acute phase of illness and as a part of multisystem inflammatory syndrome in children (MIS-C). We present a seven-month-old male who developed ICI and became a diagnostic dilemma due to viral co-infections and the gradual emergence of MIS-C during the hospital stay. We are describing this presentation in an attempt to expand the understanding of the implications of COVID-19 and MIS-C in this young and unique age group.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    儿童多系统炎症综合征(MIS-C)是最近在COVID-19大流行后儿科中描述的实体。噬血细胞性淋巴组织细胞增生症(HLH)是由巨噬细胞和T淋巴细胞的不调节增殖引起的临床综合征。这两个实体可以被认为是重叠的,尽管在文献中可以找到每种标准的不同。在这里,我们报告了一名患有COVID-19感染后MIS-C的患者,输血并发恶性疟原虫疟疾继发HLH。
    Multisystem inflammatory syndrome of childhood (MIS-C) is a recently described entity in pediatrics post-COVID-19 pandemic. Hemophagocytic lymphohistiocytosis (HLH) is a clinical syndrome caused by an unregulated proliferation of macrophages as well as T lymphocytes. Both entities can be considered overlapping, although distinct criteria for each can be found in the literature. Herein, we report a patient with MIS-C post-COVID-19 infection, complicated with HLH secondary to Plasmodium falciparum malaria from a blood transfusion.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    自大流行开始以来,已经研究了维生素D在2019年冠状病毒病(COVID-19)易感性中的作用,但是关于儿童的数据仍然很少。我们调查了维生素D状态和相关遗传变异对儿童COVID-19易损性和疾病严重程度的影响。根据系统评价和荟萃分析(PRISMA)指南的首选报告项目进行系统评价。为了确定维生素D状态和遗传多态性的报告,它们与儿童对COVID-19和儿童多系统炎症综合征(MIS-C)的易感性有关,以及补充对临床过程的影响。在最初总共279篇文章中,26项研究,在2020年9月至2023年5月之间发表的文章,最终根据纳入标准纳入本综述。11项研究提供的定量数据显示,43.05%的儿童COVID-19患者维生素D水平较低。在COVID-19病例中,平均血清25(OH)D水平明显较低,估计合并平均值为17ng/mL,由16项研究提供。维生素D缺乏和维生素D受体(VDR)FokI多态性可能提示儿科人群对COVID-19易感性的独立危险因素。25(OH)D水平可能构成与COVID-19严重程度和MIS-C相关的重要生物标志物。虽然COVID-19病例补充维生素D显示出良好的效果,对疾病结局的影响仍不确定。
    The role of vitamin D in the susceptibility to coronavirus disease 2019 (COVID-19) disease has been investigated since the beginning of the pandemic, but there is still scarce data on children. We investigated the impact of vitamin D status and the related genetic variants on COVID-19 vulnerability and severity of the disease in children. A systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, to identify reports on vitamin D status and genetic polymorphisms, their association with the susceptibility of children to COVID-19 and multisystem inflammatory syndrome in children (MIS-C), and the effect of supplementation on the clinical course. Of an initial total of 279 articles, 26 studies, published between September 2020 and May 2023, were finally included in this review according to inclusion criteria. Quantitative data provided by 11 studies revealed that 43.05% of pediatric COVID-19 patients had low vitamin D levels. Mean serum 25(OH)D levels were observed to be significantly low in COVID-19 cases, with an estimated pooled mean value of 17 ng/mL, as provided by 16 studies. Vitamin D deficiency and the vitamin D receptor (VDR) FokI polymorphism may suggest independent risk factors for susceptibility to COVID-19 in the pediatric population. The 25(OH)D level may constitute a significant biomarker associated with the COVID-19 severity and MIS-C. While supplementation of COVID-19 cases with vitamin D showed favorable results, the effect on the outcome of the disease remains uncertain.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    儿童多系统炎症综合征(MIS-C)是COVID-19的继发性免疫表现,涉及体内多个器官系统,导致发烧,皮疹,腹痛,恶心,震惊,和心脏功能障碍往往导致住院。尽管许多这些症状在抗炎治疗后缓解,MIS-C的长期神经和精神后遗症尚不清楚.在这次审查中,我们将总结MIS-C病程的两个领域,1)MIS-C大脑中的神经炎症和2)压力和住院引起的心理社会破坏。在这两个领域,我们提出了现有的临床发现,并假设了与精神病结局的潜在联系.这是首次对MIS-C患者精神病风险的整体框架进行概念化,其中包括神经炎症和心理社会风险因素。随着严重COVID-19和MIS-C病例的消退,对于临床医生来说,监测这一弱势患者人群的结局非常重要.
    Multisystem Inflammatory Syndrome in Children (MIS-C) is a secondary immune manifestation of COVID-19 involving multiple organ systems in the body, resulting in fever, skin rash, abdominal pain, nausea, shock, and cardiac dysfunction that often lead to hospitalization. Although many of these symptoms resolve following anti-inflammatory treatment, the long-term neurological and psychiatric sequelae of MIS-C are unknown. In this review, we will summarize two domains of the MIS-C disease course, 1) Neuroinflammation in the MIS-C brain and 2) Psychosocial disruptions resulting from stress and hospitalization. In both domains, we present existing clinical findings and hypothesize potential connections to psychiatric outcomes. This is the first review to conceptualize a holistic framework of psychiatric risk in MIS-C patients that includes neuroinflammatory and psychosocial risk factors. As cases of severe COVID-19 and MIS-C subside, it is important for clinicians to monitor outcomes in this vulnerable patient population.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    儿科炎症,与SARS-CoV-2感染(PIMS-TS)暂时相关的多系统综合征,也被称为儿童多系统炎症综合征(MIS-C),在暴露于SARS-CoV-2病毒后出现炎症反应不足的儿童中被诊断出。尚未解释免疫系统对先前SARS-COV-2感染的异常反应的发病机理。同样,在这组患者中接种COVID-19疫苗的安全性和有效性已成为临床讨论的主题.介绍来自许多中心的经验旨在回答这个问题。我们介绍了4例患有PIMS-TS的患者。其中三人在患病后安全接种了COVID-19疫苗。一名患者出现了与COVID-19疫苗接种暂时相关的PIMS-TS。我们还收集和讨论了其他中心的数据。
    Pediatric inflammatory, multisystem syndrome temporally associated with SARS-CoV-2 infection (PIMS-TS), also known as a multisystem inflammatory syndrome in children (MIS-C), is diagnosed in children who develop an inadequate inflammatory response after exposure to the SARS-CoV-2 virus. The pathogenesis of the abnormal response of the immune system to a previous SARS-COV-2 infection has not been explained. Similarly, the safety and effectiveness of COVID-19 vaccinations in this group of patients have become the subject of clinical discussion. Presenting experiences from many centers aims to answer this question. We present 4 cases of patients who suffered from PIMS-TS. Three of them were safely vaccinated against COVID-19 after illness. One patient developed PIMS-TS temporarily associated with COVID-19 vaccination. We also collected and discussed data from other centers.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    我们对符合条件的研究进行了综述,以评估儿童多系统炎症综合征(MIS-C)人群的患者特征。以指导未来的调查。我们全面搜索了MEDLINE,EMBASE,和Cochrane系统评价数据库,从2019年12月1日到2022年5月6日。该时间段仅限于2019年冠状病毒病(COVID-19)大流行期间。该协议已在PROSPERO注册表(CRD42022340228)中注册。符合条件的研究包括(1)诊断为MIS-C的≤21岁的儿科患者的研究人群;(2)原始的系统评价或Mata分析;(3)在2020年之后发表;(4)以英文发表。共有41项研究符合纳入标准并接受了定性分析。28项研究报告了MIS-C的结果数据。22项研究选择了MIS-C的临床特征,6项研究选择了人口统计数据作为主要主题。MIS-C患儿的死亡率为1.9%(四分位距(IQR)0.48),ICU入院率为72.6%(IQR8.3),体外膜氧合率为4.7%(IQR2.0)。一项对符合条件的研究的荟萃分析发现,MIS-C患儿的脑钠肽高于COVID-19患儿,与单独使用IVIG相比,静脉免疫球蛋白(IVIG)联合糖皮质激素治疗MIS-C的治疗失败程度较低。在未来,对于MIS-C患者,重点研究需要全身麻醉的手术的安全性,危险因素,治疗,和长期的结果是必要的。
    We conducted an Umbrella review of eligible studies to evaluate what patient features have been investigated in the multisystem inflammatory syndrome in children (MIS-C) population, in order to guide future investigations. We comprehensively searched MEDLINE, EMBASE, and Cochrane Database of Systematic Reviews from December 1, 2019 to the May 6, 2022. The time period was limited to cover the coronavirus disease-2019 (COVID-19) pandemic period. The protocol was registered in the PROSPERO registry (CRD42022340228). Eligible studies included (1) a study population of pediatric patients ≤21 years of age diagnosed with MIS-C; (2) an original Systematic review or Mata-analysis; (3) published 2020 afterward; and (4) was published in English. A total of 41 studies met inclusion criteria and underwent qualitative analysis. 28 studies reported outcome data of MIS-C. 22 studies selected clinical features of MIS-C, and 6 studies chose demographic data as a main topic. The mortality rate for children with MIS-C was 1.9% (interquartile range (IQR) 0.48), the ICU admission rate was 72.6% (IQR 8.3), and the extracorporeal membrane oxygenation rate was 4.7% (IQR 2.0). A meta-analysis of eligible studies found that cerebral natriuretic peptide in children with MIS-C was higher than that in children with COVID-19, and that the use of intravenous immunoglobulin (IVIG) in combination with glucocorticoids to treat MIS-C compared to IVIG alone was associated with lower treatment failure. In the future, for patients with MIS-C, studies focused on safety of surgery requiring general anesthesia, risk factors, treatment, and long-term outcomes are warranted.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:2019年冠状病毒病(COVID-19)在儿童中倾向于轻度表现。然而,严重和危重病例确实出现在儿科人群中,会产生使人衰弱的系统性影响,有时可能致命,值得临床医生进一步关注。同时,病原体毒力因子与宿主防御机制之间的复杂相互作用被认为在严重的COVID-19病理生理学中起着不可或缺的作用,但仍未完全了解。
    方法:由审稿人独立使用PubMed对相关出版物进行了全面的文献综述,Embase,和万方数据库。搜索关键词包括“儿童中的COVID-19”,“重症儿科COVID-19”,和“COVID-19儿童的危重病”。
    结果:儿童患严重COVID-19的风险随着合并症数量的增加和未接种疫苗的状态而升级。急性呼吸窘迫应激和坏死性肺炎是突出的肺部表现,同时也可以看到各种形式的心血管和神经系统受累。宿主对COVID-19的反应涉及多种免疫过程,包括I型干扰素和炎性体途径,其在严重和危重疾病中的失调转化为不良的临床表现。儿童多系统炎症综合征(MIS-C),与COVID-19暴露按时间顺序相关的潜在危及生命的免疫介导疾病,表示另一个科学和临床难题,举例说明了儿科免疫的复杂性。尽管儿童免疫系统和成人免疫系统之间存在相当大的差异,缺乏专门针对儿童的临床试验,目前的管理建议在很大程度上是根据成人指南改编的.
    结论:重症小儿COVID-19可影响多器官系统。严重COVID-19的免疫通路失调塑造了病程,体现了儿科免疫系统的巨大功能多样性,并强调了儿童和成人之间的免疫表型差异。因此,可能需要进一步的研究,以便在儿科特定临床实践指南中充分解决这些问题.
    Coronavirus disease 2019 (COVID-19) tends to have mild presentations in children. However, severe and critical cases do arise in the pediatric population with debilitating systemic impacts and can be fatal at times, meriting further attention from clinicians. Meanwhile, the intricate interactions between the pathogen virulence factors and host defense mechanisms are believed to play indispensable roles in severe COVID-19 pathophysiology but remain incompletely understood.
    A comprehensive literature review was conducted for pertinent publications by reviewers independently using the PubMed, Embase, and Wanfang databases. Searched keywords included \"COVID-19 in children\", \"severe pediatric COVID-19\", and \"critical illness in children with COVID-19\".
    Risks of developing severe COVID-19 in children escalate with increasing numbers of co-morbidities and an unvaccinated status. Acute respiratory distress stress and necrotizing pneumonia are prominent pulmonary manifestations, while various forms of cardiovascular and neurological involvement may also be seen. Multiple immunological processes are implicated in the host response to COVID-19 including the type I interferon and inflammasome pathways, whose dysregulation in severe and critical diseases translates into adverse clinical manifestations. Multisystem inflammatory syndrome in children (MIS-C), a potentially life-threatening immune-mediated condition chronologically associated with COVID-19 exposure, denotes another scientific and clinical conundrum that exemplifies the complexity of pediatric immunity. Despite the considerable dissimilarities between the pediatric and adult immune systems, clinical trials dedicated to children are lacking and current management recommendations are largely adapted from adult guidelines.
    Severe pediatric COVID-19 can affect multiple organ systems. The dysregulated immune pathways in severe COVID-19 shape the disease course, epitomize the vast functional diversity of the pediatric immune system and highlight the immunophenotypical differences between children and adults. Consequently, further research may be warranted to adequately address them in pediatric-specific clinical practice guidelines.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    川崎病(KD)是一种急性中血管血管炎,主要影响六个月以上的婴儿和五岁以下的儿童。它容易导致冠状动脉瘤的发展,并构成儿童获得性心脏病的主要原因。它的诊断是基于临床标准,即,发烧持续≥五天,以及该疾病的五个主要临床特征中的至少四个。偶尔,患有KD的儿童发烧,但是它们只满足了五个主要标准中的一些,这被描述为不完整的KD。此外,“非典型”KD是一个术语,通常用于出现相当不寻常的临床表现的病例,这会使临床判断复杂化,并可能延误诊断和治疗。在这个系列中,我们介绍了4例临床特征相当不寻常的KD病例:一个五岁男孩患有大叶性肺炎,一名6岁的女孩在疾病发生的第10天出现了橙棕色的色原,一个2.5个月大的婴儿,长期发烧和尿路感染,以及一名18个月大的难治性KD婴儿,高度怀疑儿童多系统炎症综合征(MIS-C)。对非典型KD的异常表现进行了文献综述,以确定必须提醒临床医生考虑该临床实体的临床发现。
    Kawasaki disease (KD) is an acute medium-vessel vasculitis, mainly affecting infants older than six months and children under five years. It predisposes to the development of coronary artery aneurysms and constitutes the leading cause of acquired heart disease in children. Its diagnosis is based on clinical criteria, namely, fever lasting for ≥ five days together with at least four of the five principal clinical features of the disease. Occasionally, children with KD present with fever, but they fulfill only some of the five principal criteria, and this is described as incomplete KD. Furthermore, \"atypical\" KD is a term that is usually used for cases that appear with rather unusual clinical manifestations, which complicate clinical judgment and may delay diagnosis and treatment. In this case series, we present four cases of KD with rather unusual clinical features: a five-year-old boy with lobar pneumonia, a six-year-old girl with orange-brown chromonychia appearing on the 10th day of the disease, a 2.5-month-old infant with prolonged fever and urinary tract infection, and an 18-month-old infant with refractory KD and high suspicion of multisystem inflammatory syndrome in children (MIS-C). A literature review on the unusual manifestations of atypical KD was performed to identify clinical findings that must alert the clinician to consider this clinical entity.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号